This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Suling, W. J.
Right arrow Articles by Barrow, W. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Suling, W. J.
Right arrow Articles by Barrow, W. W.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2000, p. 2784-2793, Vol. 44, No. 10
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Antimycobacterial Activities of 2,4-Diamino-5-Deazapteridine Derivatives and Effects on Mycobacterial Dihydrofolate Reductase

William J. Suling,1 Lainne E. Seitz,2 Vibha Pathak,2 Louise Westbrook,3 Esther W. Barrow,3 Sabrina Zywno-van-Ginkel,3 Robert C. Reynolds,2 J. Robert Piper,2 and William W. Barrow3,*

Bacteriology and Mycology Research Unit,1 Organic Chemistry,2 and Mycobacteriology Research Unit,3 Southern Research Institute, Birmingham, Alabama 35205

Received 22 May 2000/Returned for modification 19 June 2000/Accepted 12 July 2000

Development of new antimycobacterial agents for Mycobacterium avium complex (MAC) infections is important particularly for persons coinfected with human immunodeficiency virus. The objectives of this study were to evaluate the in vitro activity of 2,4-diamino-5-methyl-5-deazapteridines (DMDPs) against MAC and to assess their activities against MAC dihydrofolate reductase recombinant enzyme (rDHFR). Seventy-seven DMDP derivatives were evaluated initially for in vitro activity against one to three strains of MAC (NJ168, NJ211, and/or NJ3404). MICs were determined with 10-fold dilutions of drug and a colorimetric (Alamar Blue) microdilution broth assay. MAC rDHFR 50% inhibitory concentrations versus those of human rDHFR were also determined. Substitutions at position 5 of the pteridine moiety included -CH3, -CH2CH3, and -CH2OCH3 groups. Additionally, different substituted and unsubstituted aryl groups were linked at position 6 through a two-atom bridge of either -CH2NH, -CH2N(CH3), -CH2CH2, or -CH2S. All but 4 of the 77 derivatives were active against MAC NJ168 at concentrations of <= 13 µg/ml. Depending on the MAC strain used, 81 to 87% had MICs of <= 1.3 µg/ml. Twenty-one derivatives were >100-fold more active against MAC rDHFR than against human rDHFR. In general, selectivity was dependent on the composition of the two-atom bridge at position 6 and the attached aryl group with substitutions at the 2' and 5' positions on the phenyl ring. Using this assessment, a rational synthetic approach was implemented that resulted in a DMDP derivative that had significant intracellular activity against a MAC-infected Mono Mac 6 monocytic cell line. These results demonstrate that it is possible to synthesize pteridine derivatives that have selective activity against MAC.

* Corresponding author. Mailing address: Mycobacteriology Research Unit, Southern Research Institute, 2000 Ninth Ave. South, P.O. Box 35205, Birmingham, AL 35205. Phone: (205) 581-2139. Fax: (205) 581-2877. E-mail: barrow{at}sri.org.

Antimicrobial Agents and Chemotherapy, October 2000, p. 2784-2793, Vol. 44, No. 10
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Valderas, M. W., Barrow, W. W. (2008). Establishment of a method for evaluating intracellular antibiotic efficacy in Brucella abortus-infected Mono Mac 6 monocytes. J Antimicrob Chemother 61: 128-134 [Abstract] [Full Text]  
  • Suling, W. J., Seitz, L. E., Reynolds, R. C., Barrow, W. W. (2005). New Mycobacterium avium Antifolate Shows Synergistic Effect when Used in Combination with Dihydropteroate Synthase Inhibitors. Antimicrob. Agents Chemother. 49: 4801-4803 [Abstract] [Full Text]  
  • Barrow, E. W., Bourne, P. C., Barrow, W. W. (2004). Functional Cloning of Bacillus anthracis Dihydrofolate Reductase and Confirmation of Natural Resistance to Trimethoprim. Antimicrob. Agents Chemother. 48: 4643-4649 [Abstract] [Full Text]  
  • Long, M. C., Escuyer, V., Parker, W. B. (2003). Identification and Characterization of a Unique Adenosine Kinase from Mycobacterium tuberculosis. J. Bacteriol. 185: 6548-6555 [Abstract] [Full Text]  
  • Barrow, E. W., Westbrook, L., Bansal, N., Suling, W. J., Maddry, J. A., Parker, W. B., Barrow, W. W. (2003). Antimycobacterial activity of 2-methyl-adenosine. J Antimicrob Chemother 52: 801-808 [Abstract] [Full Text]  
  • White, E. L., Suling, W. J., Ross, L. J., Seitz, L. E., Reynolds, R. C. (2002). 2-Alkoxycarbonylaminopyridines: inhibitors of Mycobacterium tuberculosis FtsZ. J Antimicrob Chemother 50: 111-114 [Abstract] [Full Text]  
  • Suling, W. J., Maddry, J. A. (2001). Antimycobacterial activity of 1-deaza-7,8-dihydropteridine derivatives against Mycobacterium tuberculosis and Mycobacterium avium complex in vitro. J Antimicrob Chemother 47: 451-454 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»